Rapid assessment of DCLK1 inhibitors using a peptide substrate mobility shift assay

Research output: Contribution to journalArticlepeer-review

Abstract

Peptide mobility shift assays provide a sensitive measure of kinase enzymatic activity and can be used to evaluate kinase inhibitors. Herein, we describe a protocol adapted for rapid assessment of doublecortin-like kinase inhibitors. Advantages include rapid iterations of therapeutic compound assessment and the ability to characterize kinase mutations, such as drug-resistant mutants for biological rescue experiments, on kinase activity. For complete details on the use and execution of this protocol, please refer to Liu et al. (2020).

Original languageEnglish (US)
Article number100587
JournalSTAR Protocols
Volume2
Issue number2
DOIs
StatePublished - Jun 18 2021

Keywords

  • cancer
  • high-throughput screening
  • molecular/chemical probes
  • protein biochemistry

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Neuroscience(all)
  • Immunology and Microbiology(all)

Fingerprint

Dive into the research topics of 'Rapid assessment of DCLK1 inhibitors using a peptide substrate mobility shift assay'. Together they form a unique fingerprint.

Cite this